| Name | Title | Contact Details |
|---|---|---|
Karl Ensign |
Vice President for Territorial Support | Profile |
Magellan Medicaid Administration is a Glen Allen, VA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
The Wound Pros, LLC is a physician-owned Medicare Part B supplier of the industry’s most advanced wound care dressings. As a bonus, Wound Pros offers excellent clinical expertise which gives our patients the best opportunity to heal efficiently. Our vision is to change the way the world treats and manages non-healing wounds. Chronic non-healing wounds can compromise the quality of life for those living in long-term care facilities. The longer a wound remains open or unhealed, the greater the chance of unwanted complications such as infection, hospitalisation, and even amputation. At The Wound Pros, we are dedicated to meeting this challenge head-on with our "Hi-Tech Hi-Touch Approach” to wound care management. Our vision is to change the way the world treats and manages chronic non-healing wounds with better data, better decision making and better documentation.
Ampio is an innovative drug discovery and development company combining scientific, regulatory, and business capabilities to efficiently develop a robust portfolio of novel therapeutic candidates. These therapeutic candidates, if approved, will address significant inflammatory conditions for which limited treatment options exist. Ampio’s therapeutic product pipeline has been developed through more than two decades of study at leading hospital-based research centers. Rigorous preclinical and clinical research efforts have yielded a diverse portfolio of late-stage product candidates focusing on the world’s most prevalent inflammatory conditions including osteoarthritis and diabetic macular edema. Significant discoveries in both basic science and clinical research have resulted in Ampio receiving over 180 patents throughout the world, with hundreds more pending. Further, hundreds of peer-reviewed publications, abstracts, and scientific presentations highlight the depth of research supporting Ampio’s therapeutic product candidates. Ampio’s leading product candidates are Ampion™ and Optina™. The company is currently conducting the second pivotal clinical trial in the US for Ampion, a biologic intra-articular injection being studied for the treatment of osteoarthritis of the knee. Ampio is also conducting a late-stage US clinical trial for Optina, an oral agent being studied for the treatment of diabetic macular edema. Millions of patients worldwide are affected by these conditions, for which limited treatment options exist. At Ampio, we strive to offer compelling therapeutic options for the patients most in need of new treatments, and we operate every day to advance our products’ development and make these available to patients.
DocComply is a Cedar Grove, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Cherokee Nation Health Services is the largest tribally-operated health system in the country and offers a variety of services to Cherokee Nation citizens, as well as citizens of other federally recognized tribes. Through the health system, the tribe operates eight health centers and W.W. Hastings Hospital within the tribe`s 14-county jurisdiction. On the Hastings campus a 469,000 square foot outpatient health facility will also open this fall.